Herpes simplex virus latency.
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are ubiquitous human pathogens. They share with other herpesviruses the ability to establish lifelong latent infection of the host. Periodic reactivation from latency is responsible for most of the clinical disease burden of HSV infection. This review focuses on what we have learned from molecular studies in model systems of HSV latency, and the implications these findings have for treating recurrent HSV disease.
Department of Medicine, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK. rhl20@cam.ac.uk
Robin
R
Lachmann
D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D005835:Genitalia / Q000473:pathology; D016679:Genome, Viral; D006561:Herpes Simplex / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000235:genetics* / Q000254:growth & development; D018258:Herpesvirus 2, Human / Q000235:genetics* / Q000254:growth & development; D006801:Humans; D008297:Male; D009055:Mouth / Q000821:virology; D009092:Mucous Membrane / Q000821:virology; D017735:Virus Latency / Q000235:genetics*
D000998:Antiviral Agents